Comparison 3. Subgroup analysis: dose.

Outcome or subgroup title	No. of studies	No. of participants	Statistical method	Effect size
3.1 All‐cause mortality – at 28 to 30 days, or in‐hospital	11		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.1.1 Dose ≥ 1600 mg/day	8	3194	Risk Ratio (M‐H, Random, 95% CI)	1.01 [0.74, 1.39]
3.1.2 Dose < 1600 mg/day	3	265	Risk Ratio (M‐H, Random, 95% CI)	0.44 [0.13, 1.48]
3.2 All adverse events	18		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.2.1 Dose ≥ 1600 mg/day	15	4202	Risk Ratio (M‐H, Random, 95% CI)	1.33 [1.07, 1.67]
3.2.2 Dose < 1600 mg/day	3	497	Risk Ratio (M‐H, Random, 95% CI)	1.08 [0.80, 1.47]
3.3 Serious adverse events attributable to the drug	12		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.3.1 Dose ≥ 1600 mg/day	11	3117	Risk Ratio (M‐H, Random, 95% CI)	1.02 [0.75, 1.39]
3.3.2 Dose < 1600 mg/day	1	200	Risk Ratio (M‐H, Random, 95% CI)	7.00 [0.37, 133.78]
3.4 Hyperuricaemia	10		Risk Ratio (M‐H, Random, 95% CI)	Subtotals only
3.4.1 Dose ≥ 1600 mg/day	8	2210	Risk Ratio (M‐H, Random, 95% CI)	5.25 [2.62, 10.52]
3.4.2 Dose < 1600 mg/day	2	262	Risk Ratio (M‐H, Random, 95% CI)	4.88 [1.63, 14.61]